Biomarker Commons

Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

Metabolon, Inc., a diagnostics and services company offering the industry's leading biochemical profiling technology, announced today the grant of EP Patent 2,089,539B entitled, "Biomarkers Related to Metabolic Age and Methods Using the Same." The European Patent Office awarded the patent to Metabolon on December 7, 2011 and is the first patent issued to Metabolon by the EPO. The newly issued patent extends Metabolon's intellectual property (IP) related to biomarkers of metabolic age; US7,781,160, the related United States Patent, was issued by the United States Patent and Trademark Office in August 2010.

Health Discovery Corporation is pleased to announce that the United States Patent and Trademark Office has issued the first of what the Company expects to be several patents covering methods to screen for the presence of prostate cancer using genomic biomarkers that were identified by HDC researchers using the Company's patented RFE-SVM algorithm.

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 8,014,952 entitled "Serum Biomarkers in Lung Cancer" to the Company.

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Beta-2 microglobulin as a Biomarker for Peripheral Artery Disease." The patent comprises a broad range of biomarker combinations.